Multiple sclerosis research: Diagnostics, disease-modifying treatments, and emerging therapies

Kathleen Costello

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple sclerosis (MS) is a complex disease that affects the central nervous system. It is believed to be an immune mediated disease, and although the etiology remains unknown, it is believed to occur from a combination of genetic risk factors and environmental risk factors. There is no single diagnostic test for MS, and diagnostic criteria have been developed to aid the provider in making an accurate and timely diagnosis. Once a diagnosis of MS is made, treatments directed toward the inflammatory immune response should be initiated. Currently, there are 10 treatments for MS: four interferon beta products; one glatiramer acetate; one monoclonal antibody-natalizumab; three oral treatments-fingolimod, teriflunomide, and dimethyl fumarate; and one immunosuppressant agent-mitoxantrone. Each of these agents has a different administration and different risks and side effects. Numerous agents are in late stage development, and it is possible that several more agents, all with different mechanisms of action, will become available over the next several years.

Original languageEnglish (US)
Pages (from-to)S14-S23
JournalJournal of Neuroscience Nursing
Volume45
Issue number6 SUPPL. 1
DOIs
StatePublished - Dec 1 2013

Keywords

  • Alemtuzumab
  • Daclizumab
  • Dimethyl fumarate
  • Disease modifying treatment
  • Fingolimod
  • Glatiramer acetate
  • Interferon beta
  • Laquinimod
  • MCDONALD Criteria
  • Multiple sclerosis
  • Natalizumab
  • Teriflunomide

ASJC Scopus subject areas

  • Surgery
  • Endocrine and Autonomic Systems
  • Clinical Neurology
  • Medical–Surgical

Fingerprint Dive into the research topics of 'Multiple sclerosis research: Diagnostics, disease-modifying treatments, and emerging therapies'. Together they form a unique fingerprint.

Cite this